Effectiveness of ustekinumab in patients with atopic dermatitis: analysis of real-world evidence
Introduction Atopic dermatitis (AD) is a common chronic inflammatory condition. Ustekinumab is a human monoclonal antibody approved for psoriasis, that targets the interleukin (IL)-12 and IL-23, and it may also play a role in AD. Administration of ustekinumab in AD is presented in anecdotal reports...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-05-01
|
Series: | Journal of Dermatological Treatment |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/09546634.2021.1914315 |